Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules
ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l’Université de Montréal (“CHUM”) as first clinical site in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.
UTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.
CHUM has enrolled the first patient and continues to actively recruit additional patients. This milestone marks an important step forward in advancing ZYUS’ clinical development program and underscores its commitment to delivering a novel, non-opioid based pharmaceutical pain management solution to ultimately address areas of significant unmet medical need.
“Activating our first site and enrolling the first patient represents a significant step forward in advancing UTOPIA-1,” said Brent Zettl, President and CEO of ZYUS Life Sciences. “Trichomylin® softgel capsules are designed to bridge the treatment gap between conventional therapies such as opioids and NSAIDs, offering a differentiated, evidence-based pharmaceutical approach for cancer pain. With trial initiation underway, we are focused on generating meaningful clinical data to evaluate a promising new therapy that has the potential to improve patient outcomes and contribute to long-term value for shareholders.”
